期刊文献+

小剂量阿帕替尼联合卡培他滨治疗晚期三阴性乳腺癌患者临床疗效及其对中期因子和血小板第四因子水平的影响 被引量:2

下载PDF
导出
摘要 目的 分析小剂量阿帕替尼联合卡培他滨治疗晚期三阴性乳腺癌患者的临床疗效及其对中期因子(MK)和血小板第四因子(PF4)水平的影响。方法 采用抽签法将2017年10月至2019年10月在周口市中心医院诊治的123例晚期三阴性乳腺癌患者分为2组,对照组61例给予卡培他滨单药治疗,观察组62例给予小剂量阿帕替尼联合卡培他滨治疗,对比2组的临床疗效、血清MK和PF4水平、不良反应发生率。结果 观察组客观缓解率、疾病控制率均高于对照组(χ^(2)=4.673,P=0.031,χ^(2)=7.045,P=0.008)。治疗后,观察组血清MK和PF4水平均低于对照组(t=10.397,P<0.001;t=2.138,P=0.034)。2组不良反应发生率相近,且经对症处理后缓解或自行缓解,未影响治疗的顺利进行。结论 小剂量阿帕替尼联合卡培他滨对晚期三阴性乳腺癌患者效果显著,可以通过抑制血管内皮因子的生成,有效降低肿瘤细胞的发展和转移,延缓晚期乳腺癌患者的生存期,且安全性高,临床上可以推广使用。
出处 《肿瘤基础与临床》 2023年第4期338-340,共3页 journal of basic and clinical oncology
  • 相关文献

参考文献14

二级参考文献77

  • 1陈磊峰,刘天德,杜晓红,胡俊文,黄子曦,邵江华.原发性肝癌细胞中Rock2调控MMP2对其侵袭迁移的作用[J].肿瘤防治研究,2014,41(1):35-39. 被引量:10
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007,25 ( 33 ) : 5287-5312.
  • 4Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol,2007,25( 1 ) :118-145.
  • 5Hanna WM, Kwok K. Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm. Mod Pathol,2006,19(4) :481-487.
  • 6Gong Y, Sweet W, Duh YJ, et al. Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol,2009,131 (4) :490-497.
  • 7Dietel M, Ellis IO, Hofler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch ,2007,451 ( 1 ) : 19-25.
  • 8Pedersen M, Rasmussen BB. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer. Diagn Mol Pathol,2009,18 (2) :96-102.
  • 9Yaziji H, Gown AM. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? Hum Pathol, 2004, 35 (2): 143-146.
  • 10Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologie considerations. J Clin Oncol, 2009,27 (8) : 1323- 1333.

共引文献1343

同被引文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部